Unlock instant, AI-driven research and patent intelligence for your innovation.

CH2 fragment mutant of human antibody IgG and application thereof

A technology for human antibodies and mutants, applied in applications, antibody mimics/scaffolds, biochemical equipment and methods, etc., can solve problems such as poor stability, weak anti-aggregation ability, and reduced drug efficacy

Active Publication Date: 2020-07-24
武汉班科生物技术有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, antibodies developed with the wild-type CH2 fragment as the backbone have their own limitations, such as poor stability and weak anti-aggregation ability, and tend to aggregate or degrade during the process of expression, purification, storage, etc.
The immunogenicity caused by protein aggregation not only reduces the efficacy of the drug, but also brings great risks to clinical application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CH2 fragment mutant of human antibody IgG and application thereof
  • CH2 fragment mutant of human antibody IgG and application thereof
  • CH2 fragment mutant of human antibody IgG and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Embodiment 1: candidate clone screening

[0019] Before screening candidate clones, it is necessary to construct a C-terminal phage display library of CH2. The construction method is the same as the existing Chinese patent application document (201810525234.6), and the sequence of CH2 is also disclosed in this patent.

[0020] 1. Panning experiment

[0021] 1) Connect 5 tubes of TG1 bacteria, 2 mL each. Shake to OD in about 4 hours 600 = 0.6.

[0022] 2) The phage library was first heated at 80°C for 10 minutes, and then left at room temperature for 20 minutes.

[0023] 3) Closed Panning orifice plate

[0024] a) Aspirate the coated protein and wash the well plate once with PBS;

[0025] b) Add phage to BSA wells, 5 wells with 10 wells in total 12 1, the final concentration of milk was 2%, 100 μL per well. Add 3% milk to anti-CH2 wells, 200 μL per well;

[0026] c) Block for 1 h at 37°C.

[0027] 4) combine

[0028] BSA well phages were transferred to anti-CH2...

Embodiment 2

[0056]Example 2: CS-20-1, CS-20-2 molecular conformation and existing form (monomer, dimer, etc.)

[0057] AKTA analysis of CS-20-1 and CS-20-2 existing forms: the purified CS-20-1 and CS-20-2 proteins were concentrated to 1 mg / mL, PBS (pH7.4) was used as the elution buffer, Pass through Column Superdex75 Increase 10 / 300GL, wherein the flow rate is 1mL / min, and then detect its existing form.

[0058] The result is as figure 2 As shown, the protein concentration of CS-20-1, CS-20-2 and CH2 is 1mg / mL, analyzed by ColumnSuperdex75 Increase 10 / 300GL (GE Company), and compared with the standard curve, it can be found that the protein molecular weight is about 14kDa, the result indicating that they exist as monomers.

[0059] CD detection of protein molecular conformation: Dilute CS-20-1 and CS-20-2 proteins to 0.3mg / mL, PBS (pH7.4) as a control, and use different wavelength conditions at the near ultraviolet end (wavelength λ=190nm~260nm) Detect its circular dichroism, and then...

Embodiment 3

[0061] Example 3: CH2 and CS-20-1, CS-20-2 stability and anti-aggregation comparison

[0062] Anti-aggregation analysis: adjust the final concentration of CH2 and CS-20-1, CS-20-2 protein to 1mg / mL, treat in a water bath at 50°C, take samples at regular intervals, detect the absorbance at λ=320nm and record data.

[0063] Compared with the anti-aggregation strength of CH2 protein, from Figure 4 It can be found that the signals of CS-20-1 and CS-20-2 rise slowly, indicating that their anti-aggregation ability is better.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a CH2 fragment mutant of a human antibody IgG and application thereof, wherein the CH2 fragment mutant comprises CS-20-1 and CS-20-2. The new CH2 skeleton has great significance in the research and development and clinical use of monoclonal antibodies, Fc fusion proteins or antibodies developed directly with the skeleton, including stability improvement, which is conduciveto reducing production and purification cost, reducing immunogenicity caused by monoclonal antibody aggregation, etc.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a CH2 fragment mutant of human antibody IgG and its application. Background technique [0002] With its strong specificity and high sensitivity, antibodies are widely used in various fields, especially in life science research and clinical treatment such as ELISA, Western blot, immunofluorescence analysis, rapid diagnosis of diseases, and as biological agents to treat various diseases. Therefore, since entering the 21st century, people have begun to pay more and more attention to the research and development and clinical application of therapeutic antibody drugs, because it has less toxic and side effects on the human body, has natural and highly specific curative effects, and has created a huge social benefits and economic benefits. At the same time, the miniaturized antibody developed based on the CH2 fragment has good tissue penetration due to its relatively small molecular weigh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/00C12N15/13
CPCC07K16/00C07K2319/30
Inventor 龚睿
Owner 武汉班科生物技术有限公司